Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)

NCT07300969 is registered in ClinicalTrials.gov with Draig Therapeutics Ltd as lead sponsor.

NCT NCT07300969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
Lead sponsor
Draig Therapeutics Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
August 31, 2027
Enrollment
300 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)